10-Q: Amarin Reports Q1 2026 Results, Revenue Up 7%

Amarin Corporation plc announced its first quarter 2026 financial results, reporting a 7% increase in total revenue to $45.1 million, driven by growth in international product sales and licensing revenue.

Summary

• Amarin Corporation plc reported total revenue of $45.1 million for the first quarter ended March 31, 2026, a 7% increase compared to $42.0 million in the same period of 2025.
• Net product revenue increased by 6% to $43.3 million, primarily due to growth in VASCEPA sales outside the U.S.
• Licensing and royalty revenue increased by 84% to $1.8 million, driven by higher royalties from European partnerships and increased partner sales.
• Cost of goods sold increased by 62% to $27.4 million, attributed to increased product volumes.
• Gross margin decreased to 37% from 59% in the prior year, mainly due to a change in customer mix.
• Selling, general, and administrative expenses decreased by 42% to $21.1 million, largely due to cost savings from the Global Restructuring Plan.
• Research and development expenses decreased by 12% to $4.7 million.
• The company reported a net loss of $10.5 million for the quarter, an improvement from a net loss of $15.7 million in Q1 2025.
• As of March 31, 2026, Amarin had $307.8 million in cash and short-term investments and no outstanding debt.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly positive result, with revenue growth and improved net loss offset by declining gross margins and ongoing litigation risks.

Positives

• Total revenue increased by 7% to $45.1 million in Q1 2026.
• Net product revenue outside the U.S. saw a $2.3 million increase.
• Licensing and royalty revenue increased by 84% to $1.8 million.
• U.S. branded VASCEPA prescriptions increased by 17% year-over-year.
• The company's share of the U.S. icosapent ethyl market increased to approximately 48% from 42% in the prior year.
• Net loss improved to $10.5 million from $15.7 million in the prior year.
• Selling, general, and administrative expenses decreased by 42% due to restructuring efforts.
• Amarin has no outstanding debt as of March 31, 2026.
• The company has $307.8 million in cash and short-term investments, providing ample liquidity.

Negatives

• Gross margin decreased significantly to 37% from 59% in the prior year, primarily due to a change in customer mix.
• Cost of goods sold increased by 62% due to increased product volumes.
• U.S. product revenue remained flat year-over-year.
• The company continues to incur net losses, with an accumulated deficit of $1.7 billion as of March 31, 2026.

Risks

• The company faces ongoing generic competition in the U.S. market for VASCEPA.
• The outcome of ongoing litigation, including antitrust lawsuits, could materially affect the company's business.
• Reliance on third-party manufacturers and suppliers for VASCEPA API and finished product could lead to supply chain disruptions.
• Future results may be materially different from forward-looking statements due to known and unknown risks and uncertainties.
• The company's ability to successfully commercialize VASCEPA and VAZKEPA in international markets depends on its partners' efforts in obtaining regulatory approvals and pricing/reimbursement.
• The company is subject to ongoing IRS audits for its 2018 and 2019 U.S. income tax returns.

Future Outlook

Amarin expects to continue to competitively manage its market leadership in the U.S. and drive expanded access and increased patient uptake of VASCEPA through ongoing support of its commercialization partners and their pricing, reimbursement, and licensure initiatives in non-U.S. geographies. The company anticipates that licensing and royalty revenue will vary from period to period based on the timing of milestones achieved and partner sales.

Management Comments

• Despite the generic competition in the U.S., we remain confident that the global patient need for VASCEPA is high.
• For the remainder of 2026, we will continue to (i) competitively manage our market leadership in the U.S., and (ii) drive expanded access and increased patient uptake of VASCEPA through ongoing support of our commercialization partners and their pricing, reimbursement and licensure initiatives in non-U.S. geographies around the world.

Industry Context

StockSavvy.ai notes that Amarin's Q1 2026 results reflect the ongoing challenges and opportunities in the cardiovascular pharmaceutical market. The increase in international revenue and licensing income highlights the company's strategy to expand VASCEPA's global reach, while the declining gross margin due to customer mix and continued net losses underscore the impact of U.S. generic competition and the need for effective cost management.

Comparison to Industry Standards

• Amarin's gross margin of 37% for Q1 2026 is below the typical pharmaceutical industry benchmark, which often exceeds 60-70%, largely due to the shift in customer mix and pricing pressures from generic competition.
• The company's R&D spending as a percentage of revenue (approximately 10.3% in Q1 2026) is within the range for established pharmaceutical companies, though it may be considered lower for a company focused on a single key product with significant market challenges.
• The significant decrease in SG&A expenses (42%) due to restructuring aligns with industry practices for cost optimization during periods of market transition or competitive pressure.

Legal Proceedings

• A patent infringement lawsuit against Hikma is proceeding to oral arguments before the Supreme Court on April 29, 2026.
• A lawsuit filed by former CEO Karim Mikhail is ongoing, with Amarin filing a motion to dismiss on May 20, 2026.
• Antitrust lawsuits filed by Dr. Reddys, Hikma, Teva, and Apotex are ongoing, with a confidential settlement agreement reached with the Purchaser Plaintiffs on April 14, 2026.
• Six putative antitrust class action lawsuits are ongoing, alleging monopolization and conspiracy to restrain trade.

Stakeholder Impact

• Shareholders may see continued volatility due to ongoing litigation and market competition, but also potential upside from international growth and improved net loss.
• Employees may be impacted by restructuring efforts, including potential role eliminations.
• Customers (wholesalers, pharmacies) will continue to have access to VASCEPA, with potential shifts in supply dynamics.
• Creditors are not directly impacted as the company has no outstanding debt.

Next Steps

• Continue to competitively manage market leadership in the U.S.
• Drive expanded access and increased patient uptake of VASCEPA through ongoing support of commercialization partners.
• Pursue pricing, reimbursement, and licensure initiatives in non-U.S. geographies.
• Monitor business and market conditions for potential share repurchases.
• Continue to negotiate with contract suppliers to align supply arrangements with current and future global market demand.

Key Dates

Recommendation

Amarin's Q1 2026 results show revenue growth and a reduced net loss, indicating operational progress. However, the significant decline in gross margin due to market dynamics, coupled with substantial ongoing litigation and the persistent threat of generic competition in the U.S., presents considerable risks. While international expansion and licensing deals offer potential upside, the company's ability to overcome these challenges and achieve sustained profitability remains uncertain. Therefore, a 'hold' recommendation is appropriate, suggesting investors maintain their current positions while awaiting further clarity on litigation outcomes and the long-term impact of market strategies.

Keywords

Amarin Corporation plc, 10-Q, VASCEPA, VAZKEPA, icosapent ethyl, cardiovascular health, pharmaceutical, financial results, Q1 2026, revenue, net loss, REDUCE-IT, REITS, litigation